January 15th, 2026: FDA Calls for Removal of Suicide-Related Warnings from GLP-1 Drug Labels Following Review The U.S
External resources American Journal of Clinical Nutrition: Nutritional priorities to support GLP-1 therapy for obesity Endocrine Society: Protein may protect against muscle loss on semaglutide (ENDO 2025) Impact of semaglutide on body composition in adults with overweight or obesity: STEP 1 study For researchers serious about optimizing their peptide protocols and nutrition strategies during GLP-1 therapy, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, personalized calculators, and a community of thousands who have navigated these exact questions
Ethical considerations The ethical considerations of this protocol adhere to the amendment made in 2013 during the general assembly of the World Medical Association in Fortaleza, Brazil
The active ingredient in Wegovy is semaglutide , which works by mimicking the bodys glucagon-like peptide-1 (GLP-1) receptors (1)
Half the volume
A 2024 race and ethnicity analysis pooled STEP 1 and STEP 3 and reported participants as White 75.3 percent, Black 8.8 percent, Asian 10.6 percent, and other 5.3 percent